QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:APVO

Aptevo Therapeutics (APVO) Stock Forecast, Price & News

$4.63
+0.03 (+0.65%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.47
▼
$4.79
50-Day Range
$3.54
▼
$6.96
52-Week Range
$3.45
▼
$31.76
Volume
23,991 shs
Average Volume
199,058 shs
Market Capitalization
$23.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
6.36
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive APVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Aptevo Therapeutics logo

About Aptevo Therapeutics

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Headlines

May 16, 2022 | americanbankingnews.com
Piper Sandler Trims Aptevo Therapeutics (NASDAQ:APVO) Target Price to $20.00
May 15, 2022 | americanbankingnews.com
Aptevo Therapeutics (NASDAQ:APVO) Rating Lowered to Sell at StockNews.com
May 12, 2022 | finance.yahoo.com
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 1, 2022 | americanbankingnews.com
$3.75 Million in Sales Expected for Aptevo Therapeutics Inc. (NASDAQ:APVO) This Quarter
April 12, 2022 | finanznachrichten.de
Aptevo Therapeutics: APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
April 12, 2022 | finance.yahoo.com
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
March 30, 2022 | morningstar.com
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia | Morningstar
March 29, 2022 | finance.yahoo.com
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
March 24, 2022 | benzinga.com
Aptevo Therapeutics: Q4 Earnings Insights
March 24, 2022 | seekingalpha.com
Aptevo climbs as 2021 revenue more than doubles
March 24, 2022 | msn.com
Why Did Aptevo Therapeutics Stock Jump 25% Today?
March 24, 2022 | finance.yahoo.com
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
February 9, 2022 | benzinga.com
Aptevo Therapeutics Earns $10M Non-Dilutive Milestone Payment On Sales Of RUXIENCE, Provides Company Update
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APVO
Previous Symbol
CUSIP
N/A
CIK
1671584
Web
www.aptevotherapeutics.com
Phone
(206) 838-0500
Fax
206-838-0503
Employees
54
Year Founded
N/A

Sales & Book Value

Annual Sales
$12.29 million
Price / Sales
1.89
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.25 per share
Price / Book
18.52

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-28.46 million
Net Margins
-222.55%
Pretax Margin
-239.24%
Return on Equity
-396.80%
Return on Assets
-46.25%

Debt

Debt-to-Equity Ratio
3.05
Current Ratio
1.51
Quick Ratio
1.51

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
5,007,000
Free Float
4,462,000
Market Cap
$23.18 million
Optionable
Optionable

Company Calendar

Last Earnings
5/12/2022
Today
5/16/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.79 out of 5 stars

Medical Sector

811th out of 1,423 stocks

Pharmaceutical Preparations Industry

392nd out of 678 stocks

Analyst Opinion: 3.3Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -













Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

Is Aptevo Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Aptevo Therapeutics stock.
View analyst ratings for Aptevo Therapeutics or view top-rated stocks.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Aptevo Therapeutics.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) issued its quarterly earnings results on Thursday, May, 12th. The biotechnology company reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.15) by $0.40. Aptevo Therapeutics had a negative trailing twelve-month return on equity of 396.80% and a negative net margin of 222.55%.
View Aptevo Therapeutics' earnings history.

What price target have analysts set for APVO?

2 analysts have issued 1 year price targets for Aptevo Therapeutics' stock. Their forecasts range from $20.00 to $36.00. On average, they expect Aptevo Therapeutics' stock price to reach $28.00 in the next year. This suggests a possible upside of 504.8% from the stock's current price.
View analysts' price targets for Aptevo Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Aptevo Therapeutics' key executives?
Aptevo Therapeutics' management team includes the following people:
  • Mr. Marvin L. White, Pres, CEO & Director (Age 60, Pay $859.5k)
  • Mr. Jeffrey G. Lamothe CA, Exec. VP & CFO (Age 56, Pay $564.87k)
  • Ms. SoYoung Kwon J.D., LL.M., Sr. VP, Gen. Counsel, Corp. Affairs & HR
  • Dr. Fatih M. Uckun M.D., Ph.D., Chief Clinical Advisor & Consultant
What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.81%), Renaissance Technologies LLC (1.18%), Bank of New York Mellon Corp (0.52%), Northern Trust Corp (0.33%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends for Aptevo Therapeutics.

Which major investors are selling Aptevo Therapeutics stock?

APVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Northern Trust Corp.
View insider buying and selling activity for Aptevo Therapeutics or view top insider-selling stocks.

Which major investors are buying Aptevo Therapeutics stock?

APVO stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, and Vanguard Group Inc..
View insider buying and selling activity for Aptevo Therapeutics or or view top insider-buying stocks.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $4.63.

How much money does Aptevo Therapeutics make?

Aptevo Therapeutics has a market capitalization of $23.18 million and generates $12.29 million in revenue each year.

How many employees does Aptevo Therapeutics have?

Aptevo Therapeutics employs 54 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at (206) 838-0500, via email at [email protected], or via fax at 206-838-0503.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.